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Abstract 
A major challenge in the study of a new genetic entity called triplet-repeat disease is to identify the role of triplet repeats in the 
pathogenesis of the disease. We have developed a strategy to demonstrate he effect in the Y-untranslated end of the (CTG) repeats in 
myotonic dystrophy gene (MtPK) and found that repeat expansion (CTG46) causes a slight decrease in the translation rate of MtPK 
cDNA, which correlates with the finding in patients with myotonic dystrophy of a low amount of MtPK protein in muscle. These results 
provide an important clue for characterizing the genetic abnormality in other triplet-repeat diseases. 
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1. Introduction 
Myotonic Dystrophy (DM) is the most prevalent auto- 
somal dominant neuromuscular disorder with a population 
frequency of about 1 per 8000 [1]. Typical symptoms 
include tenseness of the muscle, called myotonia, and 
progressive muscle weakness, although DM is a multi-sys- 
temic disorder. Increased severity and earlier age of onset 
through the generations, o called anticipation, is also a 
unique feature of DM. The candidate gene, identified in 
1992, encodes a putative Ser/Thr protein kinase named 
myotonin protein kinase (MtPK) [2-6] and is localized to 
the long arm of human chromosome 19 (19q.13.3). It is 
known that the mutation underlying DM is the expansion 
of a (CTG) trinucleotide repeat in the 3' non-coding region 
of MtPK. Under normal circumstances, this repeat length 
is 5-37, but in patients, it expands to more than 50, and in 
extreme cases, to 1000 to 2000 [5,7]. Interestingly, it is 
known that the (CTG) repeat length correlates with the 
severity of symptoms and an early age of onset [8-12]. 
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(CTG)I9.30 could possess predisposing features making it a 
reservoir for new DM mutations [13]. The putative molecu- 
lar mass of MtPK calculated from the MtPK cDNA se- 
quence is 70 k, whereas immunoblot analysis reveals that a 
cytosolic 55 k protein cross-reacts with an anti-MtPK 
antibody [14,15]. The physiological function of MtPK, 
however, is still unknown. 
Several groups have been working on the expression of 
MtPK at the protein and mRNA levels [14,16-20]. There 
seems to be a consensus that the level of the protein 
product is decreased in the skeletal muscle of repeat-ex- 
panded patients. On the other hand, apparently conflicting 
results are obtained conceming the expression of the 
mRNA. Caskey et al. reported reduced mRNA levels in 
tissues of adult patients by using an RT-PCR method [17]. 
On the other hand, Komeluk et al. observed increased 
mRNA levels in samples from congenital patients by 
Northern blot analysis [20]. To make this discrepancy 
clear, we constructed a MtPK cDNA clone containing 
extended or deleted (CTG) repeats and analyzed the mRNA 
and protein levels of MtPK by in vitro transcription and 
immunoblot in COS-1 cells transfected with the cDNA. 
We found no significant ranscription but a slight decrease 
in MtPK protein expression for an extended repeat-con- 
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taining clone. This is the first demonstration that repeat 
expansion significantly contributes to MtPK expression. 
2. Materials and methods 
2.1. Synthesis and isolation of  the extended (CTG) repeat 
(CTG) 7 and (CAG) 7 single strand oligonucleotides were 
synthesized by a DNA synthesizer. These oligonucleotides 
were phosphorylated by T4 DNA kinase, mixed, boiled for 
5 min at 95°C, and then left at room temperature for 
annealing. The annealed nucleotide was self-ligated by 
incubation with T4 DNA ligase at 12°C for 24-48 h. The 
reaction mixture was separated by gel filtration on 
Sephacryl S-400HR (Pharmacia). 
2.2. Mutagenesis of  MtPK 
The full-length MtPK cDNA (pTV118N vector) was 
obtained as described before [21]. The number of (CTG) 
repeats in the cDNA was five. MtPK eDNA with an 
EcoT22I site in the 3'-untranslated region instead of a 
(CTG) repeat (named (CTG) 0) was made using the Sculp- 
tor TM in vitro mutagenesis system (Amersham). The muta- 
genesis primer DNA used was 5' -CCTTGTAGCCGG- 
GAATGCATGGATCACAGACCATTTC-3 ' .  The synthe- 
sized (CTG) repeat prepared above was ligated to the 
EcoT22I site and the resultant DNA was transformed to 
Escherichia coli XL-1 blue. Before ligation, each DNA 
was treated with the Klenow fragment. After collection of 
the transformed plasmid, the insertion of the repeat in the 
DNA was confirmed by restriction enzyme and PCR 
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Fig. 2. Agarose lectrophoresis of repeat-inserted MtPK eDNA. (a) MtPK plasmid DNAs were digested with PstI and electrophoresed in 1.5% agarose 
gels. (b) PCR analysis was performed using a GeneAmp PCR System 9600 (PERKIN ELMER). PCR conditions were as follows: (96°C, 10 
second ~ 62°C, 30 second ~ 72°C, 30 second) × 50 cycles. Samples were electrophoresed in 3% agarose gels. Sequence analysis revealed that he clone d 
had 46 (CTG) repeats and clone c had 37 (CAG) repeats. 
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analyses. The precise (CTG) repeat number was calculated 
by sequence analysis using a Taq DyeDeoxy terminator kit 
(Applied Byosystems Inc.). The primers used for PCR 
were oligos 101 and 102 [2]. 
2.3. In vitro transcription 
MtPK clones were ligated to pGEM vector, which has a 
T7 promotor, and the mRNA was transcribed using an 
mCAP RNA CAPPING KIT (T7 RNA polymerase, 
STRATAGENE). After incubating for 30 min at 37°C, 
mRNA samples were immediately electrophoresed on 1% 
agarose. The electrophoresed samples were stained with 
ethidium bromide (EtBr) and the density of the bands was 
analyzed by an ImageMaster TM (Pharmacia). 
2.4. Expression in COS-1 cells 
MtPK clones were ligated to pSRD vector and trans- 
fected into COS-1 cells by electroporation. After 48 or 72 
h, transfected cells were harvested and SDS-PAGE sam- 
ples were prepared by boiling whole cell samples with 
SDS sample buffer (2% SDS, 0.125 M Tris-HC1, pH 6.8, 
containing 30% glycerol, 5% 2-mercaptoethanol, and 
0.02% Bromophenol blue) for 3 min. Protein samples 
adjusted for cell number were loaded onto 10% SDS 
polyacrylamide gels. After electrophoresis, the proteins 
were electroblotted onto Immobilon immunoblot mem- 
branes (Millipore), and the filters were soaked in antibody 
solution in 25 mM phosphate buffer (pH 7.4), containing 
0.5 M NaC1 and 0.05% Tween-20. Proteins were visual- 
ized with a VECTASTAIN ABC kit (rabbit IgG, alkaline- 
phosphatase, Vector Lab). The antibody used for analysis 
was raised in rabbits using the peptide corresponding to 
the predicted peptide sequence 281-296 (DSTAETYG- 
KIVHYKEY). The peptide was synthesized by a peptide 
synthesizer (Applied Biosystems). The density of the MtPK 
protein was measured by an ImageMaster TM after normal- 
ization of the amount of protein applied in each lane. 
3. Results 
3.1. Extension of (CTG) repeat in MtPK 
We made an MtPK cDNA with an EcoT221 site in- 
stead of the (CTG) repeat in the 3' non-coding region (Fig. 
1). Electrophoretic analysis, shown in Fig. 2, indicated that 
DNAs with various (CTG) repeat lengths were success- 
fully obtained. By comparison with DNA size markers, the 
longest repeat length was about 150-200 repeats. These 
(CTG) repeat DNAs were ligated to the EcoT221 site and 
subcloned into E. coli XI-1 blue. Various lengths of 
(CTG) tandem repeat DNA were inserted into the MtPK 3' 
non-coding region. Sequence analysis showed that the 
longest (CTG) repeat was 46 repeats, although the (CTG) 
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Fig. 3. In vitro transcription f MtPK cDNA. (a) Template DNA and 
transcribed RNA were electrophoresed in 1% agarose gels. The elec- 
trophoresed samples were stained with ethidium bromide (EtBr). (b) 
Quantitation f band density. Gel images of electrophoresed amples 
were photographed and analyzed by ImageMaster TM after normalization 
for the amount of template cDNA. Significance was calculated by 
Student's t-test (n = 13). 
repeat was usually not amplified precisely by the PCR 
used for sequencing. The second longest repeat was 37 
reversed (CAG) repeats. 
3.2. In ~'itro transcription 
The (CTG)46, (CAG)37, (CTG) 5, and (CTG) 0 clones 
obtained were used for the in vitro transcription experi- 
ment (Fig. 3). Densitometry analysis of electrophoresed 
agarose gels was done repeatedly. After normalization for 
the amount of template DNA, the relative values of the 
transcribed mRNA to that of normal repeat (CTG) 5 were 
calculated. A slight decrease in transcription was observed 
in (CAG)37 and a slight increase in (CTG)46, but they were 
not significant (Student's t-test). 
3.3. Expression in COS cells 
The (CTG) 0 and (CTG)46 clones were transfected into 
COS cells to determine whether (CTG) repeat expansion 
affects the level of the translated protein. Transfected cells 
were harvested after 48-72 h, and MtPK protein was 
detected by Western blot analysis. The visualized bands 
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Fig. 4. Comparison fMtPK expression i  COS-1 cells. (a) COS-I cells 
were harvested after 48 or 72 h of transfection byelectroporation. Protein 
samples were adjusted for cell number and Western blot analysis had 
done. MtPK translated protein was pointed by arrowhead. (b) The density 
of the MtPK protein was measured byan ImageMaster TM after normaliza- 
tion of the amount of protein applied in each lane and template cDNA. 
Significance were calculated using Student's t-test (n = 10). 
were analyzed by an ImageMaster TM and the data were 
examined by Student's t-test. As shown in Fig. 4, protein 
expression of the (CTG)46 clone was less (67%) than that 
of the (CAG) 0 clone, This difference was highly signifi- 
cant (P  > 0.01). The results indicate that (CTG) repeat 
expansion down-regulates the expression of MtPK protein 
in COS cells. 
4. D iscuss ion  
Hereditary diseases that originate from an expansion of 
a (CXG) triplet-repeat DNA (triplet-repeat disease) have 
been discovered in recent years. Most of these diseases 
were found using positional cloning (Huntington's disease, 
fragile X syndrome, and myotonic dystrophy are in this 
group), and more recently other diseases (DRPLA and 
others) were discovered using triplet probes such as (CAG) 
and other triplet-repeats, or simply applying computer 
research. These triplet-repeat diseases have several unique 
features compared to hereditary diseases that follow 
Mendelian law, and have attracted world-wide attention as 
a new mechanism of disease transmission through expan- 
sion of the triplet-repeat. However, the precise biological 
meaning about triplet-repeat expansion is still unknown. 
Triplet-repeat diseases hare several common features. 
For example, all involve mental disorders and anticipation, 
although the mechanisms seem to vary. Triplet-repeat dis- 
eases can be classified into three groups on the basis of the 
location of the repeat. When the repeat is present in the 
coding region of the gene, as in the case of Huntington's 
disease, the expanded repeat may affect the conformation 
of the translated protein or give it a novel function, and 
this translated protein may cause a dominantly inherited 
disease. When the repeat exists in the 5'-non-coding re- 
gion, e.g., Fragile X syndrome, methylation of the repeat 
might occur that can shut down transcription. However, 
when the repeat is in the 3'-non-coding region, such as in 
DM, the above two assumptions cannot be applied. The 
cause of DM is thought to be an abnormal level of 
expression of mRNA and/or protein because no mutation 
is observed in the coding region. Therefore, the 3'-non- 
coding region could possess an unidentified role in the 
expression of mRNA and/or protein. Therefore it is not 
strange to speculate that the (CTG) repeat has a regulatory 
function. 
So far, there are no definite results to show whether 
there is a loss or gain of function in DM patients. Caskey 
et al. reported a reduced mRNA level [17], while Korneluk 
et al. reported an increased mRNA level in DM patients 
[20]. Carango et al. reported that the (CTG) repeat would 
affect the splicing of the mRNA and decrease the level of 
mature mRNA [19]. The increased level of mRNA ob- 
served by Komeluk et al. might correspond to the total 
amount of mRNA including both spliced and unspliced 
MtPK mRNAs [19]. In our experiments, a cDNA clone 
was used to measure both the mRNA and protein levels. 
Therefore our data is thought o clear above discrepancy of 
mRNA levels on the previous reports. We found less 
significant difference in transcription rate between clones 
with normal repeat length [(CTG) 5] and those with ex- 
panded repeat (~ 46). Since expanded repeat between 35 
to 50 is classified to pre-mutation i  DM, our (CTG)46 
may function as a pre-mutation. This may be a reason why 
we found a less detectable difference. 
Densitometry analysis of protein expression in COS-1 
cells, however, indicates, compared with (CTG) 0' the pro- 
tein level for the (CTG)46 clone is decreased to 67%. This 
result coincides with previously published ata in humans 
[14]. Our overall results suggest hat repeat expansion in 
the pre-mutation level did not take part in the expression 
of the mRNA level. On the other hand, expansion caused a 
decreased level of protein expression. Expanded (CTG) 
repeats could affect the conformation of the mRNA, and 
the protein may not be translated properly. Alternatively, 
mRNA with long (CTG) repeats might be stable and 
remain undegraded for a long time because of its abnormal 
conformation. The clone with much longer repeat will 
make its function clear. 
The results obtained in this study indicate that the 
(CTG) repeat in the 3'-untranslated region of MtPK proba- 
bly regulates the expression of mRNA and protein. Further 
116 N. Sasagawa et al. / Biochimica et Biophysica Acta 1315(1996) 112-116 
precise experiments with additional expanded (CTG) re- 
peats are essential to clarify the mechanism of (CTG) 
repeat diseases, especially DM. 
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